Heidelberg Pharma AG

Regulatory Filings • Sep 24, 2007

News Details

Corporate | 24 September 2007 09:56

WILEX AG: Phase Ib trial with WX-671 in patients with head & neck cancer successfully completed

WILEX AG / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Phase Ib trial with WX-671 in patients with head & neck cancer successfully
completed

Munich, 24 September 2007. The Munich-based biopharmaceutical company WILEX
AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard)
announced today that it has successfully completed a Phase Ib study with
its drug candidate WX-671 in patients with head & neck cancer. The study in
18 patients was conducted in several centres in Germany. The drug candidate
WX-671 was administered in different doses to patients for 15 days before
surgery.

The compound was safe and well tolerated at all dose levels tested. The
study demonstrated that the orally administered prodrug WX-671 is converted
into the active compound WX-UK1. Bioanalytical tests of the tissue from the
surgically removed tumour showed for the first time that significant
concentrations of the active metabolite WX-UK1 could be achieved in the
tumour tissue. WX-671 is being developed as part of the Company’s
urokinase-type Plasminogen Activator inhibitor programme ('uPA programme').
Currently, WX-671 is being studied in a clinical Phase II trial in
pancreatic cancer.

Dr. Paul Bevan, Head of R&D and Member of the Executive Management at WILEX
AG remarked: 'This study is an important step in our uPA development
programme. The demonstration that once daily oral doses WX-671 delivers
adequate concentrations of active WX-UK1 in tumour tissues in patients is a
significant milestone.'

About the uPA programme
WILEX’s late stage multi-product portfolio includes two drug candidates,
WX-UK1 and WX-671, which are being developed as part of the Company’s
urokinase-type Plasminogen Activator inhibitor programme ('uPA programme').
In this programme WILEX is developing various compounds that inhibit the
uPA system. The uPA system plays a key role in the growth, spread and
metastasis of various malignant tumours. The Company expects that drug
candidates which emerge from the uPA programme may be used for the
treatment of patients with tumours such as breast, pancreatic, ovarian,
gastric and colon cancer.

About WILEX
WILEX is a biopharmaceutical Company based in Munich founded in 1997 by a
team of physicians and oncologists from the Technical University of Munich.
WILEX is focused on the development of new cancer therapies based on
antibodies and small molecules. The therapeutic approach of WILEX targets
the prevention of growth, spread and the metastasis of malignant tumours
and the destruction of malignant tumours in the body. The late stage
multi-product portfolio includes both drug and medical product candidates
ranging from research to late stage clinical development. Currently the
following compounds are in clinical development: WX-G250 (development name:
RENCAREX®), WX-671, WX-UK1 and CA9-SCAN. The company’s strategy is to
develop WILEX into a commercially successful biopharmaceutical company with
a broad portfolio of new drugs and medical products for the treatment of
cancer. WILEX AG is listed at the Frankfurt Stock Exchange on the Official
Market Segment (Amtlicher Markt) / Prime Standard.
24.09.2007 Financial News transmitted by DGAP

---

Language: English
Issuer: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---